VINBARBITAL SODIUM

US Previously Marketed

First approved in 1940

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H15N2O3.Na
Molecular Weight	246.2382
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC\C=C(/C)C1(CC)C(=O)NC(=O)[N-]C1=O

InChI

InChIKey=OQLZQQCXUHKXAD-UHDJGPCESA-M

InChI=1S/C11H16N2O3.Na/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h6H,4-5H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1/b7-6+;

HIDE SMILES / InChI

Molecular Formula	C11H16N2O3
Molecular Weight	224.2563
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18879672 | https://pubchem.ncbi.nlm.nih.gov/compound/5284636

VINBARBITAL, a barbiturate derivative, is a hypnotic drug. Also, it was used for analgesia and anesthesia in obstetrics.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Psychoses 2 Sources: https://link.springer.com/article/10.1007/BF01563338	Primary		Approved 8429	DELVINAL Approved Use The best therapeutic results are obtained in patients with psychoneuroses, manic-depressive manic or mixed psychoses, toxic or infectious psychoses—and, to a lesser extent, in patients with involutional melancholia.

Doses

Dose	Population	Adverse events
32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338	Other AEs: Epigastric discomfort, Nausea... Other AEs: Epigastric discomfort (2 patients) Nausea (2 patients) Dizziness (1 patient) Sweating (3 patients) Apprehension (1 patient) Fatigue (3 patients) Sources: https://link.springer.com/article/10.1007/BF01563338

AEs

AE	Significance	Dose	Population
Apprehension	1 patient	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338
Dizziness	1 patient	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338
Epigastric discomfort	2 patients	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338
Nausea	2 patients	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338
Fatigue	3 patients	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338
Sweating	3 patients	32 mg single, oral Recommended Dose: 32 mg Route: oral Route: single Dose: 32 mg Sources: https://link.springer.com/article/10.1007/BF01563338	healthy n = 10 Health Status: healthy Population Size: 10 Sources: https://link.springer.com/article/10.1007/BF01563338

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP2B1 26

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2B1 41	inducer 1573 Sources: https://www.tandfonline.com/doi/abs/10.1080/02772249409358042 Page: 9.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1NR4T6
Chemspace	CSC009998498
Chemspace	CSC054578940
Compound Cloud	5284636
Enamine	BBV-77862075
Enamine	BBV-98679041
NCI Plated 2007	117442
NovoSeek	5284636
Smolecule	S546770	http://www.smolecule.com/products/s546770
THE BioTek	bt-286057	https://www.thebiotek.com/product/inhibitors/bt-286057
ZINC	ZINC000001707332	http://zinc15.docking.org/substances/ZINC000001707332

PubMed

Title	Date	PubMed
Vinbarbital sodium for obstetric amnesia, analgesia, and anesthesia.	1946 Mar	21017075
Vinbarbital sodium for obstetric amnesia, analgesia and anesthesia; a report of 3,000 cases.	1948 Sep	18879672
An analysis and evaluation of vinbarbital sodium for obstetric amnesia and analgesia.	1950 Mar	15405833

Substance Class	Chemical Created by `admin` on `Sat Dec 16 14:16:22 UTC 2023` Edited by `admin` on `Sat Dec 16 14:16:22 UTC 2023`
Record UNII	BAS6234GZ7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VINBARBITAL SODIUM

Common Name

English

5-ETHYL-5-(1-METHYL-1-BUTENYL)BARBITURIC ACID SODIUM SALT

Common Name

English

NSC-125758

Code

English

SODIUM VINBARBITAL

Common Name

English

VINBARBITAL SODIUM [MI]

Common Name

English

SODIUM 5-ETHYL-5-(1-METHYL-1-BUTENYL)BARBITURATE

Systematic Name

English

DELVINAL SODIUM

Brand Name

English

2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(1-METHYL-1-BUTEN-1-YL)-, SODIUM SALT (1:1)

Common Name

English

5-ETHYL-5-(1-METHYL-1-BUTENYL)-2,4,6(1H,3H,5H)-PYRIMIDINETRIONE SODIUM SALT

Common Name

English

Classification Tree Code System Code

DEA NO.

2100